📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-07 15:05
0 analysed today
0
Today
133,620
All-time analysed
40,132
Positive
6,284
Negative
79,384
Neutral
7,752
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
24 announcements match the current filters (relevance ≥ 5).
26% Revenue Growth in Q1 FY27; API Segment Surges 42% YoY
Concord Biotech reported a strong recovery in Q1 FY27 with revenues reaching ₹257 cr, a 26.2% YoY increase compared to ₹204 cr in Q1 FY26. The growth was primarily driven by the API segment, which grew 42% YoY to ₹219 cr, and a robust 46% surge in export revenues. Management has set an ambitious long-term target to reach ₹2,200 cr in API revenue over the next 5-6 years, more than doubling its current TTM revenue of ₹1,055 cr. The company is focusing on scaling its new injectable facility and its US front-end platform, Stellon Biotech, to sustain a 25% CAGR.
Confidence: HIGH
What changedThe company has moved past the regulatory and geopolitical headwinds of FY26, showing a sharp recovery in API sales and export momentum.
Why it mattersThe strong Q1 performance validates the scalability of Concord's niche fermentation platform and its ability to maintain high margins (35% OPM) while expanding into regulated markets like the US and Brazil.
Q1 FY27 Revenue: ₹257 crAPI Revenue Growth: 42% YoYExport Revenue Growth: 46% YoYLong-term API Revenue Target: ₹2,200 crTarget vs TTM Revenue: 208%Unit 1 Capacity Utilization: 78%
📅 Short termThe stock may see positive sentiment as the 26% revenue growth signals a turnaround from the previous year's stagnation.
📈 Long termThe structural shift toward injectables and direct US distribution, combined with a target to double API revenues, suggests significant long-term value creation if execution remains on track.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- De-growth in the formulation segment during Q1
- Geopolitical risks in the Middle East affecting government contracts
- Regulatory dependency for new product launches
Key Highlights
Q1 FY27 revenue grew 26.2% YoY to ₹257 cr, recovering from a challenging FY26.
API segment revenue increased 42% YoY to ₹219 cr, while export revenues grew 46% YoY.
Management targets API revenue of ₹2,200 cr in 5-6 years, compared to the current TTM revenue of ₹1,055 cr.
Unit 1 capacity utilization is at 78%, while Unit 2 stands at 55% with room for product-mix optimization.
Received US FDA approvals for Mycophenolate Mofetil and Tofacitinib tablets during the quarter.
👀 What to Watch
Monitor the utilization levels of the new injectable facility and the revenue contribution from the US front-end platform (Stellon Biotech) in upcoming quarters. Track the execution of the 25% CAGR guidance as the company transitions from API-heavy to a more balanced API and formulation mix.
26% Revenue Growth in Q1 FY27; Exports Surge 46% YoY with Margin Expansion
Concord Biotech reported a strong start to FY27 with Q1 revenue growing 26.2% YoY to ₹257.5 cr, primarily driven by a 46% surge in export revenue. EBITDA margins expanded by 190 bps to 32.0%, while core EBITDA margins (excluding new facility startup costs) remained robust at 37%. The company achieved significant regulatory milestones, including USFDA approvals for two ANDAs and successful inspections by ANVISA (Brazil). However, the formulation segment saw a 23% YoY decline, contrasting with the 42% growth in the API business.
Confidence: HIGH
What changedConcord has successfully pivoted back to growth after a challenging FY26, led by strong export demand and regulatory clearances for new products.
Why it mattersThe results validate the company's niche moat in fermentation-based APIs and its ability to expand wallet share with global clients while maintaining high margins despite new facility startup costs.
Q1 FY27 Revenue: ₹257.5 crRevenue vs TTM Revenue: 24.4%Export Growth (YoY): 46%Core EBITDA Margin: 37%Fermentation Capacity: 1,250 m3
📅 Short termThe stock may react positively to the strong export growth and margin expansion, reflecting a recovery from previous regulatory and geopolitical headwinds.
📈 Long termThe company is structurally well-positioned with a large fermentation capacity and a diversifying product mix (Injectables/CDMO) to sustain its 25% growth guidance over the next few years.
⚠ Risk flags
- 23% YoY decline in formulation revenue
- Startup costs for new facilities weighing on consolidated margins
- Geopolitical risks affecting specific government contracts
Key Highlights
Revenue from operations grew 26.2% YoY to ₹257.5 cr in Q1 FY27.
Export revenue increased by 46% YoY to ₹121.7 cr, now representing ~47% of total revenue.
EBITDA increased 34.2% YoY to ₹82.4 cr with margins improving to 32.0%.
API segment revenue grew 42% YoY to ₹218.9 cr, while Formulations declined 23% to ₹38.6 cr.
Customer concentration improved with Top 10 customers contributing 37.6% in FY26 vs 47.7% in FY22.
👀 What to Watch
Investors should monitor the utilization ramp-up at the new injectable facility and Stellon Biotech, which are critical for the 25% CAGR target. Additionally, track the recovery of the formulation segment and the impact of new ANDA launches on US market share.
Concord Biotech Q1 Results: Net Profit Up 39% YoY to ₹61.22 Cr; Revenue Grows 26%
Concord Biotech reported a strong year-on-year performance for Q1 FY27, with consolidated revenue rising 26.2% to ₹257.49 Cr compared to ₹203.99 Cr in Q1 FY26. Net profit grew 38.9% YoY to ₹61.22 Cr, reflecting improved operational efficiency in its niche fermentation API business. While YoY growth is robust, the company saw a sequential (QoQ) decline in revenue and profit by 21% and 30% respectively from the March 2026 quarter. The company also finalized the acquisition of Celliimune Biotech Private Limited on April 02, 2026.
Confidence: HIGH
What changedConcord Biotech reported its first-quarter results for FY27, showing significant YoY growth and the formal addition of Celliimune Biotech to its consolidated entity.
Why it mattersThe results validate the company's growth trajectory in the high-margin fermentation API space. Maintaining a ~31% PBT margin despite sequential volatility is critical for its premium valuation (P/E of 56.4).
Revenue (Q1 FY27): ₹257.49 CrNet Profit (Q1 FY27): ₹61.22 CrYoY Revenue Growth: 26.2%YoY Profit Growth: 38.9%EPS: ₹5.85
📅 Short termThe strong YoY growth figures are likely to be viewed positively by the market, though the sequential dip may temper immediate gains.
📈 Long termThe company's focus on complex fermentation and the ramp-up of the injectable facility supports its long-term 25% CAGR guidance. The low debt (₹1 Cr) and high ROCE (19%) provide a strong structural foundation.
⚠ Risk flags
- Sequential decline in revenue and profit compared to Q4 FY26
- Regulatory dependency on CDSCO renewals for Written Confirmations
- Geopolitical risks affecting Middle East government contracts
Key Highlights
Revenue from operations increased 26.2% YoY to ₹257.49 Cr from ₹203.99 Cr.
Consolidated Net Profit rose 38.9% YoY to ₹61.22 Cr against ₹44.06 Cr in the previous year.
Earnings Per Share (EPS) improved to ₹5.85 from ₹4.07 in the corresponding quarter last year.
Total expenses for the quarter stood at ₹18,849.49 lakhs, up from ₹15,884.08 lakhs YoY.
Acquisition of Celliimune Biotech Private Limited completed on April 02, 2026, making it a wholly-owned subsidiary.
👀 What to Watch
Monitor the utilization levels of the new injectable facility and the integration of Celliimune Biotech. Investors should watch for management's progress toward their 25% CAGR target and any updates on CDSCO renewal timelines which previously impacted sales.
₹7.55 Dividend and ₹500 Cr Loan Limit Proposed in Concord Biotech AGM Notice
Concord Biotech has scheduled its 41st AGM for July 31, 2026, proposing a final dividend of ₹7.55 per share (755% of face value) for FY26. A significant special resolution seeks approval to enhance limits for loans, guarantees, and securities to subsidiaries and associates up to ₹500 Crores. This limit represents approximately 24.7% of the company's current net worth of ₹2,019 Cr. The record date for dividend eligibility and voting has been fixed for July 24, 2026.
Confidence: HIGH
What changedThe company has formalized its dividend payout for FY26 and is seeking shareholder approval to significantly increase its capacity to fund subsidiaries and joint ventures.
Why it mattersThe ₹500 Cr loan limit indicates potential capital deployment towards growth initiatives in subsidiaries, while the dividend confirms a payout of approximately 30% of TTM PAT.
Dividend per share: ₹7.55Proposed Loan/Guarantee Limit: ₹500 CrLoan Limit vs Net Worth: ~24.7%Record Date: July 24, 2026AGM Date: July 31, 2026
📅 Short termThe stock may see mild positive interest leading up to the July 24 record date due to the dividend yield (~0.6% at current price).
📈 Long termThe increased financial flexibility to support subsidiaries aligns with the company's strategy to scale its fermentation and injectable platforms for a 25% CAGR.
⚠ Risk flags
- Related-party risks associated with loans to entities where directors may have interests
- Utilization of the ₹500 Cr limit for non-core activities
Key Highlights
Proposed final dividend of ₹7.55 per equity share for the financial year ended March 31, 2026.
Special resolution to increase loan and guarantee limits to subsidiaries/associates to ₹500 Crores.
Record date for dividend and AGM voting eligibility set for July 24, 2026.
Appointment of Mrs. Ekta Gupta as an Independent Director for a 5-year term effective June 1, 2026.
Ratification of Cost Auditor remuneration at ₹3,70,000 plus taxes for FY 2026-27.
👀 What to Watch
Investors should note the July 24 record date for dividend eligibility and monitor the AGM proceedings for management updates on the 25% CAGR growth target and injectable facility ramp-up.
Concord Biotech Unit-II Facility Clears Inspections by Kenya and Uganda Regulators
Concord Biotech has successfully completed inspections by the Pharmacy and Poisons Board (PPB) of Kenya and the National Drug Authority (NDA) of Uganda at its Unit-II formulation facility. The inspections were conducted over a seven-day period from June 18, 2026, to June 24, 2026. This regulatory clearance marks a significant milestone in the company's strategy to expand its global manufacturing and regulatory footprint. The successful outcome validates the facility's adherence to international quality standards, paving the way for increased exports to the African market.
Key Highlights
Successful completion of inspections by Kenya's PPB and Uganda's NDA at the Unit-II formulation facility.
The inspection process was conducted from June 18, 2026, to June 24, 2026.
Strengthens the company's regulatory footprint and market access in the African pharmaceutical region.
Reinforces the company's commitment to high-quality manufacturing standards and regulatory excellence.
👀 What to Watch
Investors should view this as a positive step toward geographic diversification and export growth. Monitor for future product approvals and revenue contributions from these specific African markets.
Concord Biotech to Acquire 27.38% Stake in FSGE Renewable for Rs 6.3 Crore
Concord Biotech has entered into an agreement to acquire a 27.38% equity stake in FSGE Renewable Power Private Limited for a cash consideration of Rs 6.3 Crores. This strategic investment is aimed at setting up a hybrid renewable energy plant in Gujarat with 6.3 MW Wind and 6.3 MWp Solar capacity. The project will serve as a captive power source for the company's Limbasi facility, focusing on long-term reduction of energy costs. FSGE is currently a Special Purpose Vehicle (SPV) and is expected to allot shares within 60 days.
Key Highlights
Acquisition of 27.38% equity stake in FSGE Renewable Power for Rs 6.3 Crores in cash.
Installation of a hybrid power project with 6.3 MW Wind and 6.3 MWp Solar capacity in Gujarat.
The project is dedicated to providing captive power for the company's Limbasi manufacturing facility.
Investment aims to reduce the company's carbon footprint and lower long-term operational energy costs.
FSGE is an SPV incorporated in August 2023 and has not yet commenced commercial operations.
👀 What to Watch
Investors should view this as a positive step toward operational efficiency and ESG compliance which may improve margins over the long term. Monitor the project's completion timeline and its impact on power cost savings in future earnings reports.
Concord Biotech Completes ANVISA Inspection at Limbasi API Facility
Concord Biotech Limited has successfully completed an inspection by the Brazilian Health Regulatory Agency (ANVISA) at its Limbasi API manufacturing facility. The inspection was conducted over five days from June 8 to June 12, 2026. This successful outcome is a key milestone for the company's international expansion, facilitating entry into the large Brazilian pharmaceutical market. It reinforces the company's global regulatory footprint and adherence to high-quality manufacturing standards.
Key Highlights
Successful completion of ANVISA inspection at the Limbasi API manufacturing facility.
Inspection conducted by the Brazilian Health Regulatory Agency from June 8 to June 12, 2026.
Enhances access to the Brazilian pharmaceutical market, one of the largest in the world.
Strengthens the company's global manufacturing and regulatory footprint for its API business.
👀 What to Watch
Investors should view this as a positive regulatory development that paves the way for revenue growth in the Latin American region. Monitor for future product filings and approvals in the Brazilian market following this facility clearance.
Concord Biotech Gets USFDA Approval for Tofacitinib Tablets; Targets $500M US Market
Concord Biotech has received final approval from the USFDA for its Abbreviated New Drug Application (ANDA) for Tofacitinib Tablets in 5 mg and 10 mg strengths. The drug is indicated for several chronic conditions, including rheumatoid arthritis and ulcerative colitis. The estimated U.S. market size for these specific strengths is approximately $500 million, representing a significant revenue opportunity. This approval is a key milestone in the company's strategy to expand its presence in the U.S. and international pharmaceutical markets.
Key Highlights
Received USFDA approval for Tofacitinib Tablets in 5 mg and 10 mg strengths
Addresses a U.S. market opportunity estimated at approximately $500 million
Indicated for treatment of Rheumatoid Arthritis, Psoriatic Arthritis, and Ulcerative Colitis
Strengthens the company's product portfolio and long-term growth strategy in the U.S. market
👀 What to Watch
This approval is a significant positive trigger for the stock as it opens up a large addressable market in the U.S. Investors should watch for the commercial launch timeline and subsequent market share gains.
Concord Biotech FY26 PAT Drops 30% to ₹260 Cr; Management Guides for >18% Growth in FY27
Concord Biotech reported a challenging FY26 with total revenue declining 12% to ₹829 crores and PAT falling 30% to ₹260 crores, primarily due to geopolitical headwinds and supply chain disruptions in the Middle East and Europe. Despite the decline, the company maintained a healthy adjusted EBITDA margin of 39% and remains debt-free with ₹414 crores in cash. Management has provided a positive outlook for FY27, expecting growth to exceed their historical 18% average as supply issues normalize and new facilities scale up.
Key Highlights
FY26 Revenue declined 12% YoY to ₹829 crores, with Q4 witnessing a sharper 24% degrowth.
Profit After Tax (PAT) for the full year stood at ₹260 crores, down 30% compared to the previous fiscal.
Adjusted EBITDA margin (excluding new facility expenses) remained strong at 39%, though reported margin was 35%.
Management guides for FY27 growth to be higher than the historical 18% average, supported by a strong H1 visibility.
The company is debt-free with ₹414 crores in cash and has a peak revenue potential of ₹3,000 crores from existing units.
👀 What to Watch
Investors should focus on Q1 FY27 performance to confirm the management's turnaround guidance. While FY26 was impacted by temporary external factors, the company's strong balance sheet and new injectable/US subsidiary platforms provide a base for recovery.
Concord Biotech Secures USFDA Approval for Mycophenolate Mofetil; US Market Size $30 Million
Concord Biotech Limited has received USFDA approval for its Abbreviated New Drug Application (ANDA) for Mycophenolate Mofetil for Oral Suspension USP, 200 mg/mL. This immunosuppressant is used to prevent organ rejection in kidney, heart, or liver transplant patients. The U.S. market for this specific product is estimated at approximately US$ 30 million. This approval is a key step in the company's strategy to expand its presence and product offerings in the U.S. and international markets.
Key Highlights
Received USFDA approval for Mycophenolate Mofetil for Oral Suspension USP, 200 mg/mL.
The estimated U.S. market size for this product is approximately US$ 30 million.
Indicated for prophylaxis of organ rejection in adult and pediatric transplant recipients.
Strengthens the company's position in the U.S. market and supports long-term growth strategy.
Approval follows Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
👀 What to Watch
Investors should view this as a positive development that adds a new revenue stream in the U.S. market. Monitor the company's execution in capturing market share within this $30 million segment.
Concord Biotech FY26 PAT drops 30% to ₹259 Cr amid global headwinds and procurement delays
Concord Biotech reported a challenging FY26 with consolidated revenue declining 12% YoY to ₹1,054.9 crore and PAT falling 30% to ₹259.2 crore. EBITDA margins saw significant compression, dropping to 34.8% from 42.2% in the previous year, primarily due to geopolitical tensions in the Middle East and a shift in US procurement patterns from bulk to staggered orders. Despite the financial dip, the company successfully commercialized its injectable facility and established a US subsidiary, Stellon Biotech, to strengthen its global footprint.
Key Highlights
Consolidated Revenue for FY26 decreased by 12% YoY to ₹1,054.9 crore compared to ₹1,200.1 crore in FY25.
Full-year EBITDA margin contracted by 736 bps to 34.8%, while Q4FY26 margin stood at 36.4%.
Net Profit (PAT) for the year declined by 30% YoY to ₹259.2 crore from ₹371.6 crore.
API segment remains the primary driver contributing 79% of total revenue, with formulations at 21%.
Management identified specific headwinds including a 3-month delay in EU regulatory confirmations and US Veterans Affairs tender delays.
👀 What to Watch
Investors should exercise caution due to the significant margin contraction and revenue decline, though management's optimism for an FY27 recovery backed by new injectable and soft gel facilities warrants a 'watch' for signs of turnaround in the next two quarters.
Concord Biotech Recommends ₹7.55 Dividend and Approves FY26 Financial Results
Concord Biotech's Board has recommended a final dividend of ₹7.55 per equity share for the financial year ended March 31, 2026. The company reported audited financial results for both standalone and consolidated entities with an unmodified audit opinion from BSR & Co. LLP. To strengthen governance, the board appointed Mrs. Ekta Gupta as an Additional Independent Director for a five-year term. The record date for the dividend payout is set for July 24, 2026, subject to shareholder approval.
Key Highlights
Recommended a dividend of ₹7.55 per equity share of face value ₹1 for FY 2025-26.
Fixed July 24, 2026, as the record date for identifying shareholders eligible for the dividend payout.
Appointed Mrs. Ekta Gupta as an Additional Independent Director for a 5-year term starting June 1, 2026.
Statutory auditors issued an unmodified opinion on the standalone and consolidated financial results for FY26.
Appointed Manubhai & Shah LLP and Dalwadi & Associates as Internal and Cost Auditors respectively for FY27.
👀 What to Watch
Investors should ensure they hold the shares by the record date of July 24, 2026, to qualify for the ₹7.55 dividend. The clean audit report and addition of an independent director reflect stable corporate governance.
Concord Biotech Recommends ₹7.55 Dividend; Appoints New Independent Director
Concord Biotech's board has recommended a final dividend of ₹7.55 per share for FY 2025-26, subject to shareholder approval. The company reported audited financial results for the year ended March 31, 2026, receiving a clean, unmodified opinion from its statutory auditors. In a move to strengthen governance, Mrs. Ekta Gupta has been appointed as an Additional Independent Director for a five-year term. The board also finalized the appointment of new internal and cost auditors for the 2026-27 fiscal year.
Key Highlights
Recommended a dividend of ₹7.55 per equity share of face value ₹1 each for FY 2025-26
Fixed July 24, 2026, as the record date for identifying eligible shareholders for dividend payment
Appointed Mrs. Ekta Gupta as an Additional Independent Director for a 5-year term starting June 1, 2026
Statutory auditors BSR & Co. LLP issued an unmodified audit opinion for the FY26 financial results
Appointed M/s. Manubhai & Shah LLP as Internal Auditor for the financial year 2026-27
👀 What to Watch
Investors should ensure they hold the stock before the July 24, 2026, record date to be eligible for the ₹7.55 dividend. The clean audit report and board expansion are positive indicators of corporate governance and stability.
Concord Biotech Approves FY26 Results, Recommends ₹7.55 Dividend, Appoints New Director
Concord Biotech has approved its audited financial results for the fiscal year ended March 31, 2026, with an unmodified audit opinion. The Board recommended a dividend of ₹7.55 per equity share (755% of face value), setting July 24, 2026, as the record date. Additionally, Mrs. Ekta Gupta has been appointed as an Independent Director for a five-year term starting June 1, 2026. The company also finalized the appointment of internal and cost auditors for the 2026-27 fiscal year.
Key Highlights
Recommended a dividend of ₹7.55 per equity share of face value ₹1 for FY 2025-26.
Appointed Mrs. Ekta Gupta as Additional Independent Director for a 5-year term effective June 1, 2026.
Approved audited standalone and consolidated financial results for FY26 with an unmodified audit opinion.
Fixed July 24, 2026, as the record date for dividend eligibility.
Appointed M/s. Manubhai & Shah LLP as Internal Auditor and M/s. Dalwadi & Associates as Cost Auditor for FY 2026-27.
👀 What to Watch
Investors should track the record date of July 24, 2026, to be eligible for the ₹7.55 dividend payout. The unmodified audit report and the addition of a seasoned professional to the board reflect strong governance and financial stability.
Concord Biotech Recommends ₹7.55 Final Dividend; Sets Record Date for July 2026
Concord Biotech Limited has recommended a final dividend of ₹7.55 per equity share for the financial year 2025-26. The board has fixed July 24, 2026, as the record date to determine shareholder eligibility for the payout, pending approval at the upcoming Annual General Meeting. In addition to the dividend, the company reported audited financial results for FY26 with an unmodified audit opinion from BSR & Co. LLP. The board also strengthened its governance by appointing Mrs. Ekta Gupta as an Additional Independent Director for a five-year term.
Key Highlights
Recommended a final dividend of ₹7.55 per equity share of face value ₹1 for FY 2025-26
Fixed July 24, 2026, as the record date for identifying eligible shareholders for the dividend
Appointed Mrs. Ekta Gupta as an Additional Independent Director for a 5-year term effective June 1, 2026
Statutory auditors issued an unmodified opinion on both standalone and consolidated financial results for FY26
Approved the appointment of Manubhai & Shah LLP as Internal Auditors and Dalwadi & Associates as Cost Auditors for FY 2026-27
👀 What to Watch
Investors seeking dividend income should ensure they hold shares before the July 24, 2026 record date. The unmodified audit report and board expansion reflect positive corporate governance and financial stability.
Concord Biotech Recommends ₹7.55 Dividend and Approves FY26 Audited Financial Results
Concord Biotech Limited has recommended a final dividend of ₹7.55 per equity share (face value ₹1) for the financial year 2025-26, subject to shareholder approval. The Board approved the audited standalone and consolidated financial results for the year ended March 31, 2026, with statutory auditors issuing an unmodified opinion. Additionally, the company strengthened its board by appointing Mrs. Ekta Gupta as an Additional Independent Director for a five-year term. The record date for the dividend payment has been fixed as July 24, 2026.
Key Highlights
Recommended a dividend of ₹7.55 per equity share of face value ₹1 for FY 2025-26.
Fixed July 24, 2026, as the record date for identifying eligible shareholders for dividend payment.
Appointed Mrs. Ekta Gupta as an Additional Independent Director for a 5-year term effective June 1, 2026.
Statutory auditors BSR & Co. LLP issued an unmodified audit report for both standalone and consolidated results.
Appointed M/s. Manubhai & Shah LLP and M/s. Dalwadi & Associates as Internal and Cost Auditors respectively for FY 2026-27.
👀 What to Watch
Investors should monitor the upcoming AGM for dividend approval and ensure holdings are in place by the July 24, 2026 record date to qualify for the ₹7.55 per share payout.
Concord Biotech Acquires 100% Stake in Celliimune Biotech for Rs 66 Lakhs
Concord Biotech has completed the 100% acquisition of Celliimune Biotech Private Limited for a cash consideration of Rs 66 lakhs. Celliimune is a biopharmaceutical startup focused on pioneering DNA engineering for cancer therapeutics and cell/gene therapy solutions. While the target entity currently has nil turnover, the acquisition is a strategic move to enter the high-growth oncology research space. This transaction is classified as a related party transaction as the promoter group previously held a majority stake in the target entity.
Key Highlights
Acquisition of 100% equity stake in Celliimune Biotech Private Limited for Rs 66,00,000
Target entity focuses on DNA engineering for cancer therapeutics and cell/gene therapy solutions
Celliimune was incorporated in January 2025 and currently reports nil turnover
Transaction is a related party deal as promoters previously held majority control
Acquisition completed on April 02, 2026, via cash consideration
👀 What to Watch
Investors should view this as a long-term R&D play rather than an immediate revenue driver. Monitor for future updates on clinical breakthroughs or product development from this new subsidiary.
Concord Biotech Q3 Revenue Up 14% YoY to ₹278 Cr; PAT Dips 8.5% on Exceptional Costs
Concord Biotech reported a 13.9% YoY increase in revenue from operations to ₹27,813 lakhs for Q3 FY26. However, Net Profit (PAT) declined by 8.5% YoY to ₹6,778 lakhs, primarily impacted by a one-time exceptional charge of ₹327.54 lakhs related to new labour code regulations. On a sequential basis, the company showed recovery with revenue and PAT growing 12.6% and 7.8% respectively compared to Q2 FY26. The board also strengthened its leadership by appointing Mr. Paritosh Trivedi as the new Company Secretary and Compliance Officer.
Key Highlights
Revenue from operations grew 13.9% YoY to ₹27,813.39 lakhs in Q3 FY26 compared to ₹24,422.02 lakhs in Q3 FY25.
Net Profit (PAT) for the quarter stood at ₹6,778.27 lakhs, a decline from ₹7,408.88 lakhs in the corresponding quarter last year.
Recognized an exceptional item of ₹327.54 lakhs due to the statutory impact of new labour codes on employee benefit obligations.
9-month PAT for FY26 shows a significant decline to ₹17,324.46 lakhs from ₹23,102.69 lakhs in the same period last year.
Appointed Mr. Paritosh Trivedi as Company Secretary and Compliance Officer effective February 11, 2026.
👀 What to Watch
Investors should monitor the margin pressure as PAT has declined despite healthy revenue growth. The significant year-to-date profit lag compared to the previous fiscal suggests a cautious outlook until bottom-line growth stabilizes.
Concord Biotech Q3 FY26 Revenue Grows 14% to ₹278 Cr; API Segment Surges 24%
Concord Biotech reported a recovery in Q3 FY26 with revenue growing 14% YoY to ₹278 crores, though 9-month revenue remains 5% lower at ₹729 crores due to H1 disruptions. The API business was a major driver this quarter, growing 24% to ₹219 crores, while the formulation segment saw a decline. Reported EBITDA margins stood at 35.6%, impacted by start-up costs for the new injectable facility; however, core margins remain healthy at 40%. Management expects a return to historical growth levels in FY27 as regulatory hurdles clear and the injectable business scales toward its ₹600 crore peak potential.
Key Highlights
Q3 FY26 revenue increased 14% YoY to ₹278 crores, led by strong API performance of ₹219 crores.
Adjusted EBITDA margins (excluding start-up and US subsidiary costs) remained stable at 40%.
The new injectable facility received WHO GMP certification, targeting a peak revenue of ₹600 crores.
9-month PAT stood at ₹64 crores, impacted by ₹3 crores in new labor code provisions and lower other income.
Company remains debt-free with cash and bank balances of ₹350 crores as of December 31, 2025.
👀 What to Watch
Investors should focus on the scale-up of the injectable facility and the resumption of Middle East tenders as primary growth drivers for FY27. The stock is a recovery candidate as temporary headwinds from H1 FY26, such as CDSCO delays and tariff uncertainties, have largely been resolved.
Concord Biotech Q3 Revenue Up 14% to Rs 278 Cr; EBITDA Margins Impacted by Expansion Costs
Concord Biotech reported a 14% YoY revenue growth in Q3FY26, reaching Rs 278 crore, primarily driven by a 24% surge in the API segment. However, PAT declined by 16% YoY to Rs 64 crore due to commercialization expenses for the new injectable facility and setup costs for its US subsidiary, Stellon Biotech. EBITDA margins compressed to 35.6% from 40.1% a year ago, though normalized margins remain healthy at approximately 40%. The company achieved a significant milestone by receiving WHO-GMP certification for its injectable plant, paving the way for domestic market entry.
Key Highlights
Q3FY26 Revenue grew 14% YoY to Rs 278 crore, led by robust 24% growth in the API segment.
EBITDA margins stood at 35.6%, impacted by one-time setup costs; normalized margins are at ~40%.
Received WHO-GMP certification for Unit 4 (Injectable facility), enabling domestic brand launches.
Established US subsidiary Stellon Biotech Inc. to create a direct commercial footprint in the US market.
Appointed Raviraj Karia as the new Chief Financial Officer (CFO) with 23+ years of experience.
👀 What to Watch
Investors should monitor the ramp-up of the new injectable facility and the performance of the US subsidiary, as these are the primary drivers for future growth despite current margin pressure. The long-term outlook remains positive due to specialized fermentation capabilities and global expansion.
